Preoperative chemoradiotherapy for esophageal or gastroesophageal junction cancer: results from a retrospective study using extended CROSS regimen
In patients with esophageal cancer undergoing trimodal therapy, the radiation dose escalation to 50.4 Gy was not associated with higher rates of pathological complete response or a survival benefit compared to the results of the CROSS trial. However, multivariable analysis revealed a trend toward increased mortality with larger radiation volumes. Based on these results, using modern radiotherapy techniques such as online adaptive radiotherapy might be more beneficial instead of escalating the radiation dose.
Authors
- Burim Sermaxhaj
- Tobias Haltmeier (ORCID: https://orcid.org/0000-0001-6049-9235)
- Hossein Hemmatazad (ORCID: https://orcid.org/0000-0003-4426-6188)
- Anna Stenger-Weisser
- Elena Riggenbach (ORCID: https://orcid.org/0000-0001-7278-923X)
- Martin D. Berger (ORCID: https://orcid.org/0000-0001-9224-7104)
- Yves Borbély (ORCID: https://orcid.org/0000-0003-1997-0675)
- Jennifer Brazerol
Institutions
- University of Bern (CH)
- University Hospital of Bern (CH)
- Luzerner Kantonsspital (CH)
- Stadtspital Waid (CH)
Publication Details
- Journal
- Radiation Oncology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1186/s13014-025-02637-4
- Citations
- 2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.01